Literature DB >> 26786978

The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation.

Raphael Jakubovic1, Stephanie Zhou2, Chris Heyn1, Hany Soliman2, Liyang Zhang2, Richard Aviv1, Arjun Sahgal3.   

Abstract

To investigate the predictive capacity of the apparent diffusion coefficient (ADC) as a biomarker of radiation response in brain metastases. Seventy brain metastases from 42 patients treated with either stereotactic radiosurgery or whole brain radiotherapy were imaged at baseline, 1 week, and 1 month post-treatment using diffusion-weighted MRI. Mean and median relative ADC for metastases was calculated by normalizing ADC measurements to baseline ADC. At 1 year post-treatment, or last available follow-up MRI, volume criteria determined final tumour response status. Uni- and multivariate analysis was used to account for factors associated with tumour response at 1 week and 1 month. A generalized estimating equations model took into consideration multiple tumours per subject. Optimal thresholds that distinguished responders from non-responders, as well as sensitivity and specificity were determined by receiver operator characteristic analysis and Youden's index. Lower relative ADC values distinguished responders from non-responders at 1 week and 1 month (P < 0.05). Optimal cut-off values for response were 1.060 at 1 week with a sensitivity and specificity of 75.0 and 56.3 %, respectively. At 1 month, the cut-off was 0.971 with a sensitivity and specificity of 70.0 and 68.8 %, respectively. A multivariate general estimating equations analysis identified no prior radiation [odds ratio (OR) 0.211 and 0.137, P = 0.033 and 0.0177], and a lower median relative ADC at 1 week and 1 month (OR 0.619 and 0.694, P = 0.0036 and 0.005), as predictors of tumour response. Lower relative ADC values at 1 week and 1 month following radiation distinguished responders from non-responders and may be a promising biomarker of early radiation response.

Entities:  

Keywords:  ADC; Brain metastases; MRI; Response; Stereotactic radiosurgery

Mesh:

Year:  2016        PMID: 26786978     DOI: 10.1007/s10585-016-9778-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases.

Authors:  May Tsao; Wei Xu; Arjun Sahgal
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 3.  Neuroimaging in neuro-oncology.

Authors:  Soonmee Cha
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care?

Authors:  Arjun Sahgal
Journal:  Neuro Oncol       Date:  2015-07       Impact factor: 12.300

5.  Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Authors:  W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

6.  Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.

Authors:  Reza Farjam; Christina I Tsien; Felix Y Feng; Diana Gomez-Hassan; James A Hayman; Theodore S Lawrence; Yue Cao
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.

Authors:  Caroline Chung; Shahrzad Jalali; Warren Foltz; Kelly Burrell; Petra Wildgoose; Patricia Lindsay; Christian Graves; Kevin Camphausen; Michael Milosevic; David Jaffray; Gelareh Zadeh; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-26       Impact factor: 7.038

8.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

9.  Diffusion-weighted magnetic resonance imaging of acute focal cerebral ischemia: comparison of signal intensity with changes in brain water and Na+,K(+)-ATPase activity.

Authors:  J Mintorovitch; G Y Yang; H Shimizu; J Kucharczyk; P H Chan; P R Weinstein
Journal:  J Cereb Blood Flow Metab       Date:  1994-03       Impact factor: 6.200

10.  Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases.

Authors:  Lars Hendrik Schüttrumpf; Maximilian Niyazi; Silke Birgit Nachbichler; Farkhad Manapov; Nathalie Jansen; Axel Siefert; Claus Belka
Journal:  Radiat Oncol       Date:  2014-05-02       Impact factor: 3.481

View more
  13 in total

Review 1.  Brain metastases: neuroimaging.

Authors:  Whitney B Pope
Journal:  Handb Clin Neurol       Date:  2018

2.  Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.

Authors:  Grégory Kuchcinski; Emilie Le Rhun; Alexis B Cortot; Elodie Drumez; Romain Duhal; Maxime Lalisse; Julien Dumont; Renaud Lopes; Jean-Pierre Pruvo; Xavier Leclerc; Christine Delmaire
Journal:  Eur Radiol       Date:  2017-02-16       Impact factor: 5.315

Review 3.  Quantitative sodium MR imaging: A review of its evolving role in medicine.

Authors:  Keith R Thulborn
Journal:  Neuroimage       Date:  2016-11-24       Impact factor: 6.556

4.  Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors:  Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

5.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

6.  Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model.

Authors:  Hecong Qin; Vickie Zhang; Robert A Bok; Romelyn Delos Santos; J Adam Cunha; I-Chow Hsu; Justin Delos Santos Bs; Jessie E Lee; Subramaniam Sukumar; Peder E Z Larson; Daniel B Vigneron; David M Wilson; Renuka Sriram; John Kurhanewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-25       Impact factor: 7.038

Review 7.  Current approaches to the management of brain metastases.

Authors:  John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang
Journal:  Nat Rev Clin Oncol       Date:  2020-02-20       Impact factor: 66.675

Review 8.  Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists.

Authors:  C Dodson; T J Richards; D A Smith; N H Ramaiya
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-26       Impact factor: 3.825

Review 9.  Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials.

Authors:  Amita Shukla-Dave; Nancy A Obuchowski; Thomas L Chenevert; Sachin Jambawalikar; Lawrence H Schwartz; Dariya Malyarenko; Wei Huang; Susan M Noworolski; Robert J Young; Mark S Shiroishi; Harrison Kim; Catherine Coolens; Hendrik Laue; Caroline Chung; Mark Rosen; Michael Boss; Edward F Jackson
Journal:  J Magn Reson Imaging       Date:  2018-11-19       Impact factor: 5.119

10.  Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment.

Authors:  Shoji Yomo; Kazuhiro Oguchi
Journal:  BMC Cancer       Date:  2017-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.